News
Company News: Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
– Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies
– Seed investment by Swanbridge Capital and Van Herk Ventures with support from Health~Holland
Pan Cancer T B.V., a biotech spin-off from the Erasmus Medical Center founded by Prof. Dr. Reno Debets (CSO) and Dr. Dora Hammerl (VP R&D), announces the closing of a seed investment and start of operations. Together with Katrien Reynders-Frederix (CEO), the team is committed to the discovery and development of novel TCR therapies against solid tumors such as triple negative breast cancer, bladder cancer, lung cancer, and glioma. Seed investors are Swanbridge Capital and Van Herk Ventures, and the Company is further awarded a Health~Holland grant for a public-private-partnership with Erasmus Medical Center.
Company News: Neonatal Diagnostics Company InfanDx Appoints Achim Plum as CEO
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the appointment of Dr. Achim Plum as sole Managing Director and Chief Executive Officer (CEO).
Company News: A strong partnership for the management of implant-associated infections in orthopaedics and trauma surgery
— Heraeus Medical offers quick and easy access to PRO-IMPLANT Foundation’s consultation services
— Better availability of expert advice on the treatment of complex septic complications
— Interdisciplinary recommendations on treatment concept within 24 hours
Heraeus Medical and the PRO-IMPLANT Foundation combine their expertise for optimal treatment concepts of implant-associated infections in orthopaedics and trauma surgery. In the treatment of periprosthetic joint infections (PJI), the choice of an interdisciplinary, well coordinated treatment algorithm is an essential success factor.
Company News: Omnix Medical Wins €10.8M in EIC Accelerator Funding
— Novel class of anti-infectives fighting hospital-associated infections and multi-drug resistant bacteria
— Lead program OMN6 to be advanced to proof-of-concept in humans
— Antonius Schuh appointed as Chairman of the Board of Directors
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme. The award will speed up Omnix Medical’s groundbreaking work in the fight against antimicrobial resistance based on peptides used by insects to fight bacteria.